Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 9559 · IBOGAINE Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 360bbb–0a Investigational drugs for use by eligible patients

+1 −1Shown
More for 21 U.S.C. § 360bbb–0a
Read § 360bbb–0aOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 561B(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a(b)) is amended by inserting any provision of the Controlled Substances Act (21 U.S.C. 801 et seq.) that prohibits the unauthorized use, possession, distribution, dispensation, or transportation of an eligible investigational drug, before and parts.

§ 360bbb–0a(a)–(c)

Start of § 360bbb–0a to (a)(2)(D) unchanged ·

(3) the term “phase 1 trial” means a phase 1 clinical investigation of a drug as described in section 312.21 of title 21, Code of Federal Regulations (or any successor regulations).

(b) Exemptions Eligible investigational drugs provided to eligible patients in compliance with this section are exempt from sections 352(f), 353(b)(4), 355(a), and 355(i) of this title, section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)], [inserted: any provision of the Controlled Substances Act (21 U.S.C. 801 et seq.) that prohibits the unauthorized use, possession, distribution, dispensation, or transportation of an eligible investigational drug, ]and parts 50, 56, and 312 of title 21, Code of Federal Regulations (or any successor regulations), provided that the sponsor of such eligible investigational drug or any person who manufactures, distributes, prescribes, dispenses, introduces or delivers for introduction into interstate commerce, or provides to an eligible patient an eligible investigational drug pursuant to this section is in compliance with the applicable requirements set forth in sections 312.6, 312.7, and 312.8(d)(1) of title 21, Code of Federal Regulations (or any successor regulations) that apply to investigational drugs.

(c) Use of clinical outcomes

(1) In general Notwithstanding any other provision of this chapter, the Public Health Service Act [42 U.S.C. 201 et seq.], or any other provision of Federal law, the Secretary may not use a clinical outcome associated with the use of an eligible investigational drug pursuant to this section to delay or adversely affect the review or approval of such drug under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262] unless—

Rest of § 360bbb–0a unchanged ·

21 U.S.C. § 802 Definitions

+14 −0Shown
More for 21 U.S.C. § 802
Read § 802Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended by adding at the end the following:(61) The term “ibogaine” means— (A) all parts of the plant Tabernanthe iboga; and (B) any similar compound or analog that— (i) acts on neuroplasticity, opioid receptors, or serotonergic pathways that— (I) interrupt addiction cycles; and (II) restore neurological function …

§ 802(59)–(61)

Start of § 802 to (59)(A) unchanged ·

(B) any offense that would be a felony violation of section 113 of title 18, if the offense were committed in the special maritime and territorial jurisdiction of the United States, for which the offender served a term of imprisonment of more than 12 months.

(60) The term “fentanyl-related substance” has the meaning given the term in subsection (e)(2) of schedule I of section 812(c) of this title.

(61) [inserted: The term “ibogaine” means—]

(A) [inserted: all parts of the plant Tabernanthe iboga; and]

(B) [inserted: any similar compound or analog that—]

(i) [inserted: acts on neuroplasticity, opioid receptors, or serotonergic pathways that—]

(I) [inserted: interrupt addiction cycles; and]

(II) [inserted: restore neurological function disrupted by trauma, chronic substance use, or traumatic brain injury; and]

(ii) [inserted: are distinct in mechanism from the breakthrough therapies designated under section 506 of the Federal Food, Drug, and Cosmetic Act.]

21 U.S.C. § 811 Authority and criteria for classification of substances

+7 −0Shown
More for 21 U.S.C. § 811
Read § 811Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 201 of the Controlled Substances Act (21 U.S.C. 811) is amended by adding at the end the following:(k) (1) Upon successful completion of phase 3 clinical trials for a drug in schedule I intended to treat a serious mental health disorder, the Attorney General, in consultation with the Secretary of Health and Human Services, shall initiate and complete proceedings under …

§ 811(j)–(k)

Start of § 811 to (j)(2)(A) unchanged ·

(B) the date on which the Attorney General receives notification from the Secretary of Health and Human Services that the Secretary has approved an application under section 505(c), 512, or 571 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c), 360b, 360ccc] or section 262(a) of title 42, or indexed a drug under section 572 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 360ccc–1], with respect to the drug described in paragraph (1).

(3) A rule issued by the Attorney General under paragraph (1) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor. The interim final rule shall give interested persons the opportunity to comment and to request a hearing. After the conclusion of such proceedings, the Attorney General shall issue a final rule in accordance with the scheduling criteria of subsections (b), (c), and (d) of this section and section 812(b) of this title.

(k)

(1) [inserted: Upon successful completion of phase 3 clinical trials for a drug in schedule I intended to treat a serious mental health disorder, the Attorney General, in consultation with the Secretary of Health and Human Services, shall initiate and complete proceedings under subsection (a) to determine whether to place such drug in another schedule.]

(2) [inserted: The Attorney General shall complete proceedings under subsection (a) for a drug as quickly as practicable.]

(3) [inserted: In this subsection, the term “phase 3 clinical trial” means phase 3 clinical investigations conducted pursuant to an exemption for investigational use under section 505(i) of the Federal Food, Drug, and Cosmetic Act or section 351(a)(3) of the Public Health Service Act.]

21 U.S.C. § 823 Registration requirements

+60 −0Shown
More for 21 U.S.C. § 823
Read § 823Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following:(p) Special registration for schedule I eligible investigational drugs under right to try.— (1) Definitions.— In this subsection, the terms “eligible investigational drug” and “eligible patient” have the meanings given those terms in section 561B of the Federal Food, Drug, and …

§ 823(o)–(p)

Start of § 823 to (o)(1)(B) unchanged ·

(C) how the process and criteria described in subparagraph (B) differ from the process and criteria applicable to applications to conduct research with other controlled substances in the same schedule.

(2) Timing of posting The Attorney General shall make information described in paragraph (1) public upon making a determination described in that paragraph, regardless of whether a practitioner has submitted such an application at that time.

(p) [inserted: Special registration for schedule I eligible investigational drugs under right to try.—]

(1) [inserted: Definitions.—] [inserted: In this subsection, the terms “eligible investigational drug” and “eligible patient” have the meanings given those terms in section 561B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a).]

(2) [inserted: Special registration process.—] [inserted: The Attorney General shall register physicians to directly administer eligible investigational drugs in schedule I to eligible patients under section 561B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a) in accordance with paragraphs (3) through (6) of this subsection.]

(3) [inserted: Requirements.—]

(A) [inserted: Application.—] [inserted: A physician desiring a registration to directly administer an eligible investigational drug as described in paragraph (2) shall submit to the Attorney General an application containing—]

(i) [inserted: evidence of a valid registration to dispense or administer controlled substances in schedules II through V;]

(ii) [inserted: evidence of compliance with section 561B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a), including—]

(I) [inserted: documentation from the manufacturer or sponsor verifying the investigational drug in schedule I is an eligible investigational drug;]

(II) [inserted: an agreement from the manufacturer or sponsor to supply the eligible investigational drug, along with guidance on its administration, to the requesting physician for the treatment of eligible patients; and]

(III) [inserted: an affirmation that the physician will only directly administer the eligible investigational drug to treat eligible patients in a manner consistent with the guidance provided by the manufacturer or sponsor;]

(iii) [inserted: the quantity of the eligible investigational drug to be supplied by the manufacturer or sponsor to the physician to treat eligible patients;]

(iv) [inserted: evidence that the physician is allowed to treat patients under the laws of the State in which the treatment will take place;]

(v) [inserted: a description of the site at which the physician intends to store and administer the eligible investigational drug; and]

(vi) [inserted: any additional information the Attorney General determines necessary to prevent diversion.]

(B) [inserted: Approval.—] [inserted: Not later than 45 days after receiving an application containing the information required under subparagraph (A), the Attorney General shall—]

(i) [inserted: register the applicant; or]

(ii) [inserted: serve an order to show cause upon the applicant in accordance with section 304(c).]

(4) [inserted: Electronic submissions.—] [inserted: The Attorney General shall provide a means for a physician to submit an application under paragraph (3)(A) electronically.]

(5) [inserted: Limitation on amounts.—] [inserted: A physician treating eligible patients with an eligible investigational drug in schedule I under this subsection may only possess the amounts of the eligible investigational drug identified in—]

(A) [inserted: the application submitted to the Attorney General under paragraph (3)(A); or]

(B) [inserted: a supplemental notification that the physician may submit to the Attorney General if the physician needs additional amounts of the eligible investigational drug for the treatment of eligible patients, which supplemental notification—]

(i) [inserted: shall include—]

(I) [inserted: the name of the physician;]

(II) [inserted: the additional quantity of the eligible investigational drug needed; and]

(III) [inserted: an attestation that the treatment with the eligible investigational drug is consistent with the scope of treatment that was the subject of the application under paragraph (3)(A); and]

(ii) [inserted: shall be deemed approved on the date that is 30 days after the date on which the physician submits the supplemental notification to the Attorney General, unless the Attorney General serves an order to show cause upon the applicant in accordance with section 304(c).]

(6) [inserted: Single registration for related treatment sites.—] [inserted: A physician may treat eligible patients with an eligible investigational drug in schedule I under a single registration under this subsection if—]

(A) [inserted: the treatment occurs exclusively on sites all of which are—]

(i) [inserted: within the same city or county; and]

(ii) [inserted: under the control of the same institution, organization, or agency; and]

(B) [inserted: before commencing the treatment, the physician notifies the Attorney General of each site where the eligible investigational drug will be stored or administered in accordance with paragraph (3)(A)(vi).]

21 U.S.C. § 826 Production quotas for controlled substances

+17 −3Shown
More for 21 U.S.C. § 826
Read § 826Only this section
7 changes the bill asks for here, 7 carried out
  1. Carried out:

    by striking total;

  2. Carried out:

    by inserting clinical, after research,; and

  3. Carried out:

    by inserting and paragraph (3) after (2);

  4. Carried out:

    in paragraph (2), by inserting , in consultation with the Secretary of Health and Human Services, after if the Attorney General determines; and

  5. Carried out:

    by adding at the end the following:(3) The Attorney General shall revise the annually established production quotas within 90 days for any basic class of controlled substance in schedule I, and within 60 days for any basic class of controlled substance in schedule II, if any of the following triggering events …

  6. Carried out:

    in subsection (c), by adding at the end the following: Upon the occurrence of a triggering event listed in subsection (a)(3) with respect to a controlled substance, a registered manufacturer may apply for an expedited mid-year adjustment of the manufacturing quota determined for such manufacturer under this subsection with respect to such controlled substance.; and

  7. Carried out:

    by adding at the end the following:(j) The Attorney General shall establish annual sufficiency standards for each established production quota at levels necessary to meet the legitimate medical, scientific, research, clinical, and industrial needs of the United States..

§ 826(a)–(e)

§ 826. Production quotas for controlled substances

(a) Establishment of total annual needs

(1) The Attorney General shall determine the [struck: total ]quantity and establish production quotas for each basic class of controlled substance in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured each calendar year to provide for the estimated medical, scientific, research, [inserted: clinical, ]and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. Except as provided in paragraph (2)[inserted: and paragraph (3)], production quotas shall be established in terms of quantities of each basic class of controlled substance and not in terms of individual pharmaceutical dosage forms prepared from or containing such a controlled substance.

(2) The Attorney General may, if the Attorney General determines[inserted: ,] [inserted: in consultation with the Secretary of Health and Human Services, ]it will assist in avoiding the overproduction, shortages, or diversion of a controlled substance, establish an aggregate or individual production quota under this subsection, or a procurement quota established by the Attorney General by regulation, in terms of pharmaceutical dosage forms prepared from or containing the controlled substance.

(3) [inserted: The Attorney General shall revise the annually established production quotas within 90 days for any basic class of controlled substance in schedule I, and within 60 days for any basic class of controlled substance in schedule II, if any of the following triggering events occurs during the calendar year:]

(A) [inserted: A controlled substance in schedule I or II is transferred or placed into another class of controlled substances in accordance with applicable law.]

(B) [inserted: A controlled substance in schedule I or II is approved or cleared by the Food and Drug Administration in accordance with the Federal Food, Drug, and Cosmetic Act.]

(C) [inserted: A controlled substance in schedule I or II is designated as a breakthrough therapy under section 506 of such Act.]

(D) [inserted: An exemption for investigational use is granted for a drug in schedule I or II investigational use under section 505(i) of such Act.]

(E) [inserted: A drug in schedule I or II is approved by the Food and Drug Administration for use in a phase 3 clinical trial.]

(b) Individual manufacturing quotas; revised quotas The Attorney General shall limit or reduce individual manufacturing quotas to the extent necessary to prevent the aggregate of individual quotas from exceeding the amount determined necessary each year by the Attorney General under subsection (a). The quota of each registered manufacturer for each basic class of controlled substance in schedule I or II or for ephedrine, pseudoephedrine, or phenylpropanolamine shall be revised in the same proportion as the limitation or reduction of the aggregate of the quotas. However, if any registrant, before the issuance of a limitation or reduction in quota, has manufactured in excess of his revised quota, the amount of the excess shall be subtracted from his quota for the following year.

(c) Manufacturing quotas for registered manufacturers On or before December 1 of each year, upon application therefor by a registered manufacturer, the Attorney General shall fix a manufacturing quota for the basic classes of controlled substances in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine that the manufacturer seeks to produce. The quota shall be subject to the provisions of subsections (a) and (b) of this section. In fixing such quotas, the Attorney General shall determine the manufacturer’s estimated disposal, inventory, and other requirements for the calendar year; and, in making his determination, the Attorney General shall consider the manufacturer’s current rate of disposal, the trend of the national disposal rate during the preceding calendar year, the manufacturer’s production cycle and inventory position, the economic availability of raw materials, yield and stability problems, emergencies such as strikes and fires, and other factors.[inserted: Upon the occurrence of a triggering event listed in subsection (a)(3) with respect to a controlled substance, a registered manufacturer may apply for an expedited mid-year adjustment of the manufacturing quota determined for such manufacturer under this subsection with respect to such controlled substance.]

(d) Quotas for registrants who have not manufactured controlled substance during one or more preceding years The Attorney General shall, upon application and subject to the provisions of subsections (a) and (b) of this section, fix a quota for a basic class of controlled substance in schedule I or II for any registrant who has not manufactured that basic class of controlled substance or ephedrine, pseudoephedrine, or phenylpropanolamine during one or more preceding calendar years. In fixing such quota, the Attorney General shall take into account the registrant’s reasonably anticipated requirements for the current year; and, in making his determination of such requirements, he shall consider such factors specified in subsection (c) of this section as may be relevant.

(e) Quota increases At any time during the year any registrant who has applied for or received a manufacturing quota for a basic class of controlled substance in schedule I or II or for ephedrine, pseudoephedrine, or phenylpropanolamine may apply for an increase in that quota to meet his estimated disposal, inventory, and other requirements during the remainder of that year. In passing upon the application the Attorney General shall take into consideration any occurrences since the filing of the registrant’s initial quota application that may require an increased manufacturing rate by the registrant during the balance of the year. In passing upon the application the Attorney General may also take into account the amount, if any, by which the determination of the Attorney General under subsection (a) of this section exceeds the aggregate of the quotas of all registrants under this section.

§ 826(i)–(j)

(f)–(i) unchanged ·

(A) take into consideration changes in the accepted medical use of the covered controlled substances; and

(B) work with the Secretary of Health and Human Services on methods to appropriately and anonymously estimate the type and amount of covered controlled substances that are submitted for collection from approved drug collection receptacles, mail-back programs, and take-back events.

(j) [inserted: The Attorney General shall establish annual sufficiency standards for each established production quota at levels necessary to meet the legitimate medical, scientific, research, clinical, and industrial needs of the United States.]

Step through the changes